Selected research
Industry Research
Meningococcal Disease Treatment Industry Research Report 2026
Market perspective
The global Meningococcal Disease Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Meningococcal Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Meningococcal Disease Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Meningococcal Disease Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Meningococcal Disease Treatment include Walvax Biotechnology Co.,Ltd., Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Beijing Minhai Biological Technology Co.,Ltd., CanSino Biologics Inc., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and Hebei Hejia Pharmaceutical Technology Group Co., Ltd, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Meningococcal Disease Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Meningococcal Disease Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Meningococcal Disease Treatment Market by Company
Walvax Biotechnology Co.,Ltd.
Apeloa Pharmaceutical Co.,Ltd.
Novartis
Merck Sharp & Dohme
Beijing Minhai Biological Technology Co.,Ltd.
CanSino Biologics Inc.
Shandong Jincheng Pharmaceutical Group Co.,ltd.
Pfizer
Hebei Hejia Pharmaceutical Technology Group Co., Ltd
GlaxoSmithKline
Chengdu Institute of Biology
Sanofi Pasteur
Meningococcal Disease Treatment Segment by Type
Antibiotics
Vaccines
Meningococcal Disease Treatment Segment by Application
Hospitals
Drugstores
Others
Meningococcal Disease Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Meningococcal Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antibiotics
- Vaccines
Applications
- Hospitals
- Drugstores
- Others
Companies covered
- Walvax Biotechnology Co.,Ltd.
- Apeloa Pharmaceutical Co.,Ltd.
- Novartis
- Merck Sharp & Dohme
- Beijing Minhai Biological Technology Co.,Ltd.
- CanSino Biologics Inc.
- Shandong Jincheng Pharmaceutical Group Co.,ltd.
- Pfizer
- Hebei Hejia Pharmaceutical Technology Group Co., Ltd
- GlaxoSmithKline
- Chengdu Institute of Biology
- Sanofi Pasteur
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Meningococcal Disease Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Antibiotics
- 2.2.3 Vaccines
- 2.3 Meningococcal Disease Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Drugstores
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Meningococcal Disease Treatment Breakdown Data by Type
- 3.1 Global Meningococcal Disease Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Meningococcal Disease Treatment Forecasted Market Size by Type (2027-2032)
4 Meningococcal Disease Treatment Breakdown Data by Application
- 4.1 Global Meningococcal Disease Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Meningococcal Disease Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Meningococcal Disease Treatment Market Perspective (2021-2032)
- 5.2 Global Meningococcal Disease Treatment Growth Trends by Region
- 5.2.1 Global Meningococcal Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Meningococcal Disease Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Meningococcal Disease Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Meningococcal Disease Treatment Market Dynamics
- 5.3.1 Meningococcal Disease Treatment Industry Trends
- 5.3.2 Meningococcal Disease Treatment Market Drivers
- 5.3.3 Meningococcal Disease Treatment Market Challenges
- 5.3.4 Meningococcal Disease Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Meningococcal Disease Treatment Players by Revenue
- 6.1.1 Global Top Meningococcal Disease Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Meningococcal Disease Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Meningococcal Disease Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Meningococcal Disease Treatment Head Office and Area Served
- 6.4 Global Meningococcal Disease Treatment Players, Product Type & Application
- 6.5 Global Meningococcal Disease Treatment Manufacturers Established Date
- 6.6 Global Meningococcal Disease Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Meningococcal Disease Treatment Market Size (2021-2032)
- 7.2 North America Meningococcal Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Meningococcal Disease Treatment Market Size by Country (2021-2026)
- 7.4 North America Meningococcal Disease Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Meningococcal Disease Treatment Market Size (2021-2032)
- 8.2 Europe Meningococcal Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Meningococcal Disease Treatment Market Size by Country (2021-2026)
- 8.4 Europe Meningococcal Disease Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Meningococcal Disease Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Meningococcal Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Meningococcal Disease Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Meningococcal Disease Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Meningococcal Disease Treatment Market Size (2021-2032)
- 10.2 South America Meningococcal Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Meningococcal Disease Treatment Market Size by Country (2021-2026)
- 10.4 South America Meningococcal Disease Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Meningococcal Disease Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Meningococcal Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Walvax Biotechnology Co.,Ltd.
- 12.1.1 Walvax Biotechnology Co.,Ltd. Company Information
- 12.1.2 Walvax Biotechnology Co.,Ltd. Business Overview
- 12.1.3 Walvax Biotechnology Co.,Ltd. Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.1.4 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
- 12.1.5 Walvax Biotechnology Co.,Ltd. Recent Developments
- 12.2 Apeloa Pharmaceutical Co.,Ltd.
- 12.2.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
- 12.2.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
- 12.2.3 Apeloa Pharmaceutical Co.,Ltd. Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.2.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
- 12.2.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.3.4 Novartis Meningococcal Disease Treatment Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Merck Sharp & Dohme
- 12.4.1 Merck Sharp & Dohme Company Information
- 12.4.2 Merck Sharp & Dohme Business Overview
- 12.4.3 Merck Sharp & Dohme Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.4.4 Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio
- 12.4.5 Merck Sharp & Dohme Recent Developments
- 12.5 Beijing Minhai Biological Technology Co.,Ltd.
- 12.5.1 Beijing Minhai Biological Technology Co.,Ltd. Company Information
- 12.5.2 Beijing Minhai Biological Technology Co.,Ltd. Business Overview
- 12.5.3 Beijing Minhai Biological Technology Co.,Ltd. Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.5.4 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
- 12.5.5 Beijing Minhai Biological Technology Co.,Ltd. Recent Developments
- 12.6 CanSino Biologics Inc.
- 12.6.1 CanSino Biologics Inc. Company Information
- 12.6.2 CanSino Biologics Inc. Business Overview
- 12.6.3 CanSino Biologics Inc. Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.6.4 CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio
- 12.6.5 CanSino Biologics Inc. Recent Developments
- 12.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
- 12.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
- 12.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
- 12.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio
- 12.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.8.4 Pfizer Meningococcal Disease Treatment Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
- 12.9.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
- 12.9.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
- 12.9.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.9.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio
- 12.9.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
- 12.10 GlaxoSmithKline
- 12.10.1 GlaxoSmithKline Company Information
- 12.10.2 GlaxoSmithKline Business Overview
- 12.10.3 GlaxoSmithKline Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.10.4 GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio
- 12.10.5 GlaxoSmithKline Recent Developments
- 12.11 Chengdu Institute of Biology
- 12.11.1 Chengdu Institute of Biology Company Information
- 12.11.2 Chengdu Institute of Biology Business Overview
- 12.11.3 Chengdu Institute of Biology Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.11.4 Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio
- 12.11.5 Chengdu Institute of Biology Recent Developments
- 12.12 Sanofi Pasteur
- 12.12.1 Sanofi Pasteur Company Information
- 12.12.2 Sanofi Pasteur Business Overview
- 12.12.3 Sanofi Pasteur Revenue in Meningococcal Disease Treatment Business (2021-2026)
- 12.12.4 Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio
- 12.12.5 Sanofi Pasteur Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst